甲状腺相关性眼病的靶向治疗研究进展  

Recent Progress in the Therapeutic Targets of Thyroid-Associated Ophthalmopathy

作　　者：徐巍龙[1] 余江毅[2] 

机构地区：[1]南京中医药大学第一临床医学院 [2]江苏省中医院内分泌科,南京210029

出　　处：《医学综述》2016年第2期287-290,共4页Medical Recapitulate

摘　　要：甲状腺相关性眼病(TAO)是一种目前难以控制的内分泌系统疾病,机制尚未完全阐明。其早期暂无有效防控手段,一旦起病,严重影响患者眼球运动、视力、外观,极大地降低了患者的生活质量。目前采取的治疗方案主要有激素冲击治疗、球后放疗、手术治疗、免疫抑制治疗、中西医结合治疗等,疗效有限且不良反应大。但随着分子生物学的发展,出现了很多新的治疗思路。The thyroid-associated ophthalmopaty（TAO） is one kind of endocrine system disease which is hard to control up to now. The mechanism of this disease is not fully elucidated, besides there is no method to prevent TAO from happening, which would seriously influence patients＇eye movement, vision, appearance and lower the life quality once happens. Glucocorticoids, radiation therapy, surgery,immunosuppressive therapy and combined treatment of Chinese and western medicine are major therapies of TAO so far,which have limited effect but great adverse reactions. Rescently, with the development of molecular biology, new therapies have been emerging.

关 键 词：甲状腺相关性眼病 机制 靶向治疗 

分 类 号：R581.9[医药卫生—内分泌]